Gilder Gagnon Howe & Co’s Adverum Biotechnologies ADVM Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4,456	Closed	-$111K	–	283
2017 Q2	$111K	Sell	4,456 -87	-2%	-$2.38K	﹤0.01%	263
2017 Q1	$123K	Sell	4,543 -545	-11%	-$15.5K	﹤0.01%	248
2016 Q4	$148K	Hold	5,088	–	–	﹤0.01%	227
2016 Q3	$209K	Sell	5,088 -1	-0%	-$38	﹤0.01%	228
2016 Q2	$161K	Sell	5,089 -9	-0.2%	-$407	﹤0.01%	236
2016 Q1	$264K	Buy	+5,098	New	+$285K	0.01%	194
2015 Q2	–	Sell	-547	Closed	-$222K	–	277
2015 Q1	$222K	Buy	+547	New	+$231K	﹤0.01%	234

Other funds holding ADVM

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Gilder Gagnon Howe & Co's ADVM Position: Q3 2017 in Review

Gilder Gagnon Howe & Co sold out of Adverum Biotechnologies (ADVM) in Q3 2017, closing a stake of 4,456 shares — an estimated $111K sold.

Gilder Gagnon Howe & Co first reported a position in ADVM in Q1 2015 and held it in 7 quarters. The position peaked at $264K in Q1 2016. 58 funds tracked by Wall St. Rank hold ADVM as of Q3 2017.

Gilder Gagnon Howe & Co reported no remaining Adverum Biotechnologies position as of Q3 2017 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 4,456 Adverum Biotechnologies shares in Q3 2017, an estimated $111K.
Gilder Gagnon Howe & Co first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 7 quarters.
Gilder Gagnon Howe & Co's Adverum Biotechnologies position peaked at $264K in Q1 2016.
58 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2017, filed 6 Nov 2017.